PCM Trials has acquired US-based EmVenio Research, a community-based clinical trial site provider equipped with mobile research units, to design a patient-centric approach for hybrid and DCTs.
A provider of mobile research nurse visits for DCTs, PCM Trials intends to bolster its capabilities in recruiting and retaining diverse populations for clinical research studies, a key requirement for regulatory approval.
The collaboration between PCM Trials and EmVenio addresses the long-standing concerns of regulatory bodies, such as the Food and Drug Administration (FDA), regarding the underrepresentation of minority groups in clinical trials.
Site networks are vital to offer trial data for sponsors.
With the acquisition, PCM Trials will have access to a site network focused on serving an underrepresented population of patients in priorly hard-to-reach communities. This will aid the company to work flexibly with sponsors to facilitate them in meeting study goals.
EmVenio activated 63 mobile sites for trials in more than 22 US states and ten locations in the UK, achieving a broad demographic reach.
Notably, sites of EmVenio report more than 50% diverse patient participation across all locations.
Last month, PCM Trials completed the acquisition of Netherlands-based Clinical Trial Service (CTS) to enhance its ability and reach to carry out studies across the globe.
PCM Trials president Greg Austin said: “The acquisition of EmVenio is an important part of our company’s overall strategy to further remove barriers for patients of all backgrounds and ethnicities to participate in clinical research, creating the most patient-centric clinical trial model.
“Our pioneering approach to using Certified Mobile Research Nurses who visit patients in their homes has already been shown to improve both patient retention and diversity in clinical trials and drive faster study completion.
“Now, with the addition of EmVenio’s mobile research site network, we have the unmatched ability to provide additional convenience for prospective participants, empowering community-based clinical trial access.”
